Skip to content
Open access

Recurrence of cardiovascular events despite achieving LDL-C <1.4 mmol/L i in patients with coronary artery disease

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

Given the association of on-treatment LDL-C <40 mg/dL with a reduced risk of MACE, further lower LDL-C level may be more favourable therapeutic goal for the secondary prevention of ASCVD in patients with CAD.

Abstract

The current ESC/EAS guideline recommends lowering LDL-C <1.4 mmol/L for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in very high-risk patients. However, despite favourable LDL-C control, atherosclerosis still continues to progress, which eventually causes cardiovascular events. Therefore, identification of factors associated with the aforementioned residual cardiovascular risks is clinically needed. To characterize patients with CAD who experienced recurrence of ASCVD despite achieving LDL-C levels <1.4 mmol/L. The current study was a multi-center, retrospective analysis of 780 patients with CAD who achieved on-treatment LDL-C <55 mg/dL after PCI. MACE was defined as a composite of cardiac death, non-fatal MI and clinically driven coronary revascularization at non-culprit segments. Clinical demographics were compared between patients with and without MACE. During the observational period [median=1632 days], MACE occurred in 6.2% (=48/780) of study population. Following the control of LDL-C <55 mg/dL, 81.2% (=39/48) of MACE mainly occurred within 2 years after PCI (Figure 1). There were no significant differences in the frequency of traditional coronary risk factors between the two groups. Patients experiencing MACE more likely exhibited polyvascular disease (72.9 vs. 17.3%, p<0.001). In particular, the concomitance of LEAD (54.2 vs. 4.0%, p<0.001) and both LEAD and CVD (12.5 vs. 1.6%, p<0.001) was more frequently observed in patients experiencing MACE. Statin and high-intensity statin were frequently used in both groups (statin=94.8%, p=0.218, high-intensity statin=73.3%, p=0.198), whereas patients with MACE less likely received ezetimibe (45.8 vs. 63.2%, p=0.023) (Figure 1). Consequently, a lower proportion of on-treatment LDL-C <40 mg/dL was observed in those with MACE (16.7 vs. 33.2%, p=0.018). On multivariate analysis, polyvascular disease (HR=10.74, 95%CI=5.65-20.39, p<0.001) and on-treatment LDL-C <40 mg/dL (HR=0.37, 95%CI=0.17-0.81, p=0.012) were independently associated with MACE (Figure 1). Notably, the concomitance of LEAD (HR=21.03, 95%CI=10.74-41.17, p<0.001) but not cerebrovascular disease (HR=1.63, 95%CI=0.46-5.75, p=0.447) elevated a risk of MACE. In patients with polyvascular disease (n=162), on-treatment LDL-C <40 mg/dL was associated with a lower frequency of MACE (HR=0.35, 95%CI=0.14-0.87, p=0.024) (Figure 2). On-going cardiovascular risks existed despite achieving LDL-C <55 mg/dL. Multivariate analysis emerged polyvascular disease as an independent factor associated with cardiovascular outcomes after the attainment of LDL-C <55 mg/dL. Given the association of on-treatment LDL-C <40 mg/dL with a reduced risk of MACE, further lower LDL-C level may be more favourable therapeutic goal for the secondary prevention of ASCVD in patients with CAD.

Read PDF

Similar papers

Open access Oct 2026

Sex-difference in cardiovascular outcomes following achieved LDL-C Levels <1.0 mmol/L in patients with coronary artery disease

Women with cardiovascular disease still continue to present substantially higher mortality than men, which highlights the need for appropriate anti-atherosclerotic management. Current ESC/EAS guidelines advocate achieving stricter LDL-C goals (<1.0 and 1.4 mmol/L) for the secondary prevention of ASCVD in very hig...

F. Matsuyama, Y. Katatoka, S. Kitahara et al. · 0 citations
Open access Oct 2026

The independent association of mortality with LDL-C management, and number and types of atherosclerotic cardiovascular disease events: a large nationwide real-world cohort study

In a large nationwide cohort, recurrent ASCVD events and multi-bed disease were associated with markedly higher mortality compared to patients experiencing single ASCVD events, highlighting the need for earlier, more intensive, and sustained prevention- particularly aggressive LDL-C lowering and comprehensive risk fact...

M. H. Moshe Hoshen, V. B. Vishal Bali, S. Moser et al. · 0 citations
Review Oct 2026

[LDL-c and residual cardiovascular risk in patients with coronary artery disease].

Although the expanding therapeutic armamentarium allows for increased substantial LDL-c reductions, this has not translated into a corresponding improvement in target attainment and the underlying reasons are complex and multifactorial.

Thomas de Saint Nicolas, Hubert Dromas, Gilles Lemesle · 0 citations
Open access Oct 2026

Editorial Comment: LDL-C Reduction After CABG With Low-Dose Statin Therapy: Implications for Secondary Prevention

Coronary artery bypass grafting (CABG) is an established revascularization procedure for patients with advanced coronary artery disease. However, surgical revascularization does not eliminate the underlying atherosclerotic process or the risk of subsequent cardiovascular events. Effective lipid-lowering therapy therefo...

A. Niazi, Benazir Mikrani, Haris Mehmood · 0 citations
Open access Oct 2026

LDL-c levels and clinical outcomes in acute myocardial infarction patients with prior ischemic stroke

The optimal low-density lipoprotein cholesterol (LDL-c) target after acute myocardial infarction (AMI) in patients with prior ischemic stroke remains uncertain, particularly regarding the trade-off between ischemic protection and bleeding risk. We evaluated the association between LDL-c levels achieved at three m...

Y.-K. Zhang, R. Guo, Z. Xue et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.